Prognostic Index for Cancer Outcomes
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–0
- Intermediate Risk1–1
- High Risk2–2
The Prognostic Index for Cancer Outcomes calculates predicting cancer mortality from serum biomarkers using C-reactive protein (CRP) and white blood cell (WBC) count. Key inputs include crp. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts cancer mortality from serum biomarkers using C-reactive protein (CRP) and white blood cell (WBC) count. This simple two-parameter scoring system provides risk stratification for cancer patients and helps guide prognostic discussions and clinical decision-making across multiple cancer types.
Clinical Indication
The Prognostic Index for Cancer Outcomes is indicated for bedside clinical practice to support Predicts cancer mortality from serum biomarkers using C-reactive protein (CRP) and white blood cell (WBC) count. This simple two-parameter scoring system provides risk stratification for cancer patients and helps guide prognostic discussions and clinical decision-making across multiple cancer types.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Survival outcomes vary significantly depending on cancer type, stage, and treatment.
Score = CRP points + WBC points (where CRP >10 mg/L = 1 point, WBC >11 × 10⁹/L = 1 point)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| crp | string | Yes | C-reactive protein (CRP) level in mg/L(mg/L) |
| wbc_count | string | Yes | White blood cell (WBC) count in 10⁹/L(×10⁹/L) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Low Risk | Minimal inflammatory response |
| 1–1 | Intermediate Risk | Moderate inflammatory response |
| 2–2 | High Risk | Significant inflammatory response |
Evidence-Based References (EBM)
- Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107(4):695-9. doi: 10.1038/bjc.2012.292.DOI: 10.1038/bjc.2012.292
- Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633-41. doi: 10.1016/j.ejca.2011.03.028.DOI: 10.1016/j.ejca.2011.03.028
- McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-40. doi: 10.1016/j.ctrv.2012.08.003.DOI: 10.1016/j.ctrv.2012.08.003